PYXS Pyxis Oncology, Inc.
$1.84▲ +8.88%
Healthcare
Other
After hours
$1.84▲ +0.00%
Oct 27, 4:01 PM ET
Volume 1.18M
Avg Volume (10D) 837.0K
Key Metrics & Fundamentals
Market Cap
$219.80M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.03 - 5.55
% vs 50 MA
-32.67%
% vs 200 MA
-14.79%
RSI-14
37.3
MACD Histogram
+0.0300
Beta (1Y vs SPY)
1.31
Free Cash Flow
-$18.21M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$25.69M
COGS
–
Operating Exp
$25.99M
Operating Income
-$25.99M
EBIT
-$25.99M
Pretax Income
-$25.35M
Net Income
-$25.35M
EPS (Diluted)
-0.40
Price & Volume History
Loading chart…
Recent News
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
GlobeNewswire · Oct 27, 2026 8:45 AM ET
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
GlobeNewswire · Oct 2, 2026 7:00 AM ET
Update: Pyxis Oncology Shares Fall After Pricing Public Offering of Common Stock, Warrants
MT Newswires · Sep 30, 2026 2:46 PM ET
Pyxis Oncology Prices Public Offering of Common Stock, Warrants
MT Newswires · Sep 30, 2026 3:58 AM ET
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
GlobeNewswire · Sep 30, 2026 1:11 AM ET
Pyxis Oncology stock falls on public offering announcement
Investing.com · Sep 29, 2026 5:19 PM ET
Pyxis Oncology Announces Proposed Public Offering
GlobeNewswire · Sep 29, 2026 4:24 PM ET
Wedbush Lifts Price Target on Pyxis Oncology to $8 From $6, Keeps Outperform Rating
MT Newswires · Sep 9, 2026 10:13 AM ET
Pyxis Oncology shares fall 7% despite updated MICVO trial results
InvestorsHub · Sep 9, 2026 10:08 AM ET
Pyxis Oncology Reports 36% Response Rate in Phase 1 MICVO Study
MT Newswires · Sep 9, 2026 8:26 AM ET
Financial Overview - Income Statement
Quarterly
Dec 2025
See PYXS's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.